Neumora Therapeutics (NASDAQ:NMRA) Issues Earnings Results

Neumora Therapeutics (NASDAQ:NMRA) released its quarterly earnings results on Tuesday. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.07), Briefing.com reports. During the same quarter last year, the company posted ($1.14) EPS.

Neumora Therapeutics Stock Performance

Shares of NMRA opened at $11.31 on Wednesday. The stock has a 50-day moving average of $13.08 and a two-hundred day moving average of $11.41. The stock has a market cap of $1.81 billion, a P/E ratio of -4.42 and a beta of 3.92. Neumora Therapeutics has a one year low of $8.33 and a one year high of $21.00.

Insider Activity

In related news, CFO Joshua Pinto sold 31,642 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $11.78, for a total value of $372,742.76. Following the sale, the chief financial officer now owns 154,658 shares in the company, valued at $1,821,871.24. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Robert A. Lenz sold 30,788 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total value of $363,606.28. Following the completion of the transaction, the insider now owns 339,205 shares of the company’s stock, valued at $4,006,011.05. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Joshua Pinto sold 31,642 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $11.78, for a total value of $372,742.76. Following the sale, the chief financial officer now directly owns 154,658 shares in the company, valued at approximately $1,821,871.24. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 110,538 shares of company stock valued at $1,390,513. Company insiders own 26.40% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on NMRA shares. HC Wainwright assumed coverage on shares of Neumora Therapeutics in a research note on Tuesday, October 1st. They issued a “buy” rating and a $30.00 target price for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $29.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. JPMorgan Chase & Co. downgraded Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $18.00 to $15.00 in a research note on Tuesday, November 5th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Neumora Therapeutics in a research note on Wednesday. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Neumora Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.67.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.